Rahul Ballal

Rahul Ballal is an accomplished executive in the biopharmaceutical sector, currently serving as CEO of Mediar Therapeutics and holding board positions at InduPro, Enliven Therapeutics, Agios Pharmaceuticals, and Vaderis Therapeutics AG. With extensive experience in developing novel therapies, Rahul leads Mediar's innovative approach to fibrosis treatment while contributing to multiple companies focused on rare diseases and precision oncology. Previously, Rahul held roles as CEO of Imara, Vice President of Business Development at Flexion Therapeutics, and Entrepreneur in Residence at Versant Ventures, among other positions. Educationally, Rahul holds a Ph.D. in Biochemistry and Molecular Biology from Georgetown University School of Medicine, a Master’s degree in Bioinformatics from The Johns Hopkins University, and a Bachelor’s degree in Biology from Brown University.